{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:41:11Z","timestamp":1775227271904,"version":"3.50.1"},"reference-count":95,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Applied Sciences"],"abstract":"<jats:p>Bone and joint infections (BJI) remain among the most challenging conditions in orthopaedics due to their complex pathophysiology, frequent association with biofilm formation on bone and implant surfaces, and the rising prevalence of antibiotic-resistant pathogens. Conventional antibiotic therapies, although central to current clinical practice, are often limited by poor biofilm penetration, disruption of the host microbiota, and the increasing emergence of multidrug resistance, particularly in chronic infections such as osteomyelitis and prosthetic joint infections. This review provides a comprehensive exploration of bacteriophage therapy as a targeted, non-antibiotic strategy for the management of BJIs. Bacteriophages exhibit unique biological characteristics, including strict host specificity, self-amplifying antibacterial activity, and the capacity to disrupt biofilms through bacterial lysis and phage-derived enzymes. Evidence from in vitro investigations, animal models, and emerging clinical studies demonstrates the promising efficacy of phages and phage lysins against key BJI pathogens, particularly Staphylococcus aureus, with favourable safety profiles and encouraging rates of infection control, especially when used as adjuncts to surgery and antibiotics. Despite this potential, challenges such as narrow host range, variable pharmacokinetics, immunogenicity, and underdeveloped regulatory frameworks continue to limit widespread clinical adoption. Addressing these barriers through standardized phage selection, improved delivery strategies, combination therapies, and coordinated regulatory efforts will be critical to realizing the full therapeutic potential of phage-based interventions for antibiotic-resistant bone and joint infections.<\/jats:p>","DOI":"10.3390\/app16042002","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:50:30Z","timestamp":1771401030000},"page":"2002","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phage Therapy for Bone and Joint Infections: Challenges, Biological Dynamics, and Therapeutic Prospects in the Era of Antimicrobial Resistance"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-106X","authenticated-orcid":false,"given":"Maria Pia","family":"Ferraz","sequence":"first","affiliation":[{"name":"Departamento de Engenharia Mec\u00e2nica, Faculdade de Engenharia, Universidade do Porto, 4200-465 Porto, Portugal"},{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4099-002 Porto, Portugal"},{"name":"Instituto de Engenharia Biom\u00e9dica, Universidade do Porto, 4099-002 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e000518","DOI":"10.1136\/bmjgh-2017-000518","article-title":"Antimicrobial resistance and universal health coverage","volume":"2","author":"Bloom","year":"2017","journal-title":"BMJ Glob. Health"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ferraz, M.P. (2024). Antimicrobial Resistance: The Impact from and on Society According to One Health Approach. Societies, 14.","DOI":"10.3390\/soc14090187"},{"key":"ref_3","unstructured":"World Health Organization (2025, December 26). Antimicrobial Resistance. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance."},{"key":"ref_4","unstructured":"World Health Organization (2025, December 26). Lack of Innovation Set to Undermine Antibiotic Performance and Health Gains. Available online: https:\/\/www.who.int\/news\/item\/22-06-2022-22-06-2022-lack-of-innovation-set-to-undermine-antibiotic-performance-and-health-gains."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/jac\/dkaf293","article-title":"Phages connect the biological dots of antimicrobial resistance: From genesis and spread to alternative treatment modules","volume":"80","author":"Anastassopoulou","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10883","DOI":"10.1038\/s41467-025-64608-3","article-title":"Considerations and perspectives on phage therapy from the transatlantic taskforce on antimicrobial resistance","volume":"16","author":"Moon","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Fuerst-Wilmes, M., Respondek, V., Schramm, M., Lilienthal, N., Buss, K., and Duechting, A. (2025). Regulation of phage therapy medicinal products: Developments, challenges, and opportunities. Front. Cell Infect. Microbiol., 15.","DOI":"10.3389\/fcimb.2025.1631359"},{"key":"ref_8","first-page":"173","article-title":"Phage Therapy: A Different Approach to Fight Bacterial Infections","volume":"16","author":"Hibstu","year":"2022","journal-title":"Biologics"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2022.11.017","article-title":"Phage therapy: From biological mechanisms to future directions","volume":"186","author":"Strathdee","year":"2023","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Niazi, S.K. (2025). Bacteriophage Therapy: Discovery, Development, and FDA Approval Pathways. Pharmaceuticals, 18.","DOI":"10.3390\/ph18081115"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e187996","DOI":"10.1172\/JCI187996","article-title":"Bacteriophage therapy for multidrug-resistant infections: Current technologies and therapeutic approaches","volume":"135","author":"Kim","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"107088","DOI":"10.1016\/j.micpath.2024.107088","article-title":"Phage therapy: A targeted approach to overcoming antibiotic resistance","volume":"197","author":"Olawade","year":"2024","journal-title":"Microb. Pathog."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e1260","DOI":"10.1002\/mbo3.1260","article-title":"Impact of antibiotics on the human microbiome and consequences for host health","volume":"11","author":"Patangia","year":"2022","journal-title":"Microbiologyopen"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3390\/idr16060092","article-title":"Advancing Phage Therapy: A Comprehensive Review of the Safety, Efficacy, and Future Prospects for the Targeted Treatment of Bacterial Infections","volume":"16","author":"Palma","year":"2024","journal-title":"Infect. Dis. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Fukaya-Shiba, A., Ogata, A., Kuribayashi, R., Sakurai, A., Suzuki, K., Takadama, S., Nishimura, J., Uchiyama, J., Ohge, H., and Takeuchi, T. (2025). Regulatory considerations for developing phage therapy medicinal products for the treatment of antimicrobial resistant bacterial infections. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1713471"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"109595","DOI":"10.1016\/j.isci.2024.109595","article-title":"Bacterial resistance to temperate phage is influenced by the frequency of lysogenic establishment","volume":"27","author":"Baaziz","year":"2024","journal-title":"iScience"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Abedon, S.T. (2025). Phage Therapy: Combating Evolution of Bacterial Resistance to Phages. Viruses, 17.","DOI":"10.3390\/v17081094"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijantimicag.2019.06.007","article-title":"Lytic bacteriophages against multidrug-resistant Staphylococcus aureus, Enterococcus faecalis and Escherichia coli isolates from orthopaedic implant-associated infections","volume":"54","author":"Barros","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102145","DOI":"10.1016\/j.nano.2019.102145","article-title":"Encapsulated bacteriophages in alginate-nanohydroxyapatite hydrogel as a novel delivery system to prevent orthopedic implant-associated infections","volume":"24","author":"Barros","year":"2020","journal-title":"Nanomedicine"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Barros, J., Monteiro, F.J., and Ferraz, M.P. (2022). Bioengineering Approaches to Fight against Orthopedic Biomaterials Related-Infections. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911658"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/femsre\/fuaa017","article-title":"Current challenges and future opportunities of phage therapy","volume":"44","author":"Pires","year":"2020","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"110657","DOI":"10.1016\/j.virol.2025.110657","article-title":"The broad-spectrum kayvirus phage disrupts biofilms formed by methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylococcus pseudintermedius","volume":"611","author":"Apiratwarrasakul","year":"2025","journal-title":"Virology"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lafranca, T., Bonkat, G., Rieken, M., and Braissant, O. (2025). Efficacy of a commercial bacteriophage cocktail against planktonic cells and both thin and thick biofilms of skin pathogens, measured using isothermal microcalorimetry. Front. Microbiol., 16.","DOI":"10.3389\/fmicb.2025.1608243"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1186\/s40001-025-02781-3","article-title":"Efficacy of phage therapy in controlling staphylococcal biofilms: A systematic review","volume":"30","author":"Mobarezi","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Topka-Bielecka, G., Dydecka, A., Necel, A., Bloch, S., Nejman-Fale\u0144czyk, B., W\u0119grzyn, G., and W\u0119grzyn, A. (2021). Bacteriophage-Derived Depolymerases against Bacterial Biofilm. Antibiotics, 10.","DOI":"10.3390\/antibiotics10020175"},{"key":"ref_26","first-page":"e2020024","article-title":"Bacteriophages presence in nature and their role in the natural selection of bacterial populations","volume":"91","author":"Naureen","year":"2020","journal-title":"Acta Biomed."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jiph.2021.10.020","article-title":"Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects","volume":"14","author":"Uddin","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Gordon, M., and Ramirez, P. (2024). Efficacy and Experience of Bacteriophages in Biofilm-Related Infections. Antibiotics, 13.","DOI":"10.3390\/antibiotics13020125"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Husain, F.M., Zahra, A., Ali, A., Kamthan, M., Al-Shabib, N.A., Farooqui, Z., Ahmad, N., Albalawi, T., Alam, P., and Munawar, N. (2025). Bacteriophages and Their Enzymes: Allies Against Microbial Biofilms. Pharmaceuticals, 18.","DOI":"10.3390\/ph18121771"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.cmi.2023.01.021","article-title":"Pharmacokinetics\/pharmacodynamics of phage therapy: A major hurdle to clinical translation","volume":"29","author":"Nang","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.cmp.2025.11.003","article-title":"Bacterial resistance to phage therapy: Mechanisms and strategies to overcome it","volume":"18","author":"Karamlou","year":"2025","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/0113892010347488250113171505","article-title":"Navigating Regulatory Frameworks and Compliances for Bacteriophages as Therapeutic Agents","volume":"27","author":"Kaistha","year":"2025","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4161\/viru.25991","article-title":"A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens","volume":"5","author":"Wittebole","year":"2014","journal-title":"Virulence"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4161\/bact.1.1.14942","article-title":"Phages in nature","volume":"1","author":"Clokie","year":"2011","journal-title":"Bacteriophage"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Fernandes, S., and S\u00e3o-Jos\u00e9, C. (2018). Enzymes and Mechanisms Employed by Tailed Bacteriophages to Breach the Bacterial Cell Barriers. Viruses, 10.","DOI":"10.3390\/v10080396"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4161\/bact.20757","article-title":"The strange history of phage therapy","volume":"2","author":"Summers","year":"2012","journal-title":"Bacteriophage"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4292\/wjgpt.v8.i3.162","article-title":"Phage therapy: An alternative to antibiotics in the age of multi-drug resistance","volume":"8","author":"Lin","year":"2017","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.7861\/clinmedicine.18-2-150","article-title":"Bone and joint infection","volume":"18","author":"Colston","year":"2018","journal-title":"Clin. Med."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Tsikopoulos, K., and Meroni, G. (2023). Periprosthetic Joint Infection Diagnosis: A Narrative Review. Antibiotics, 12.","DOI":"10.3390\/antibiotics12101485"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Stubnya, B.G., Schulz, M., V\u00e1ncsa, S., Szil\u00e1gyi, G.S., Szatm\u00e1ri, A., and Bejek, Z. (2025). Global Trends in Joint Arthroplasty: A Systematic Review and Future Projections. J. Clin. Med., 14.","DOI":"10.3390\/jcm14228214"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e01910-14","DOI":"10.1128\/mBio.01910-14","article-title":"Clinical characteristics and outcomes of prosthetic joint infection caused by small colony variant staphylococci","volume":"5","author":"Tande","year":"2014","journal-title":"mBio"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1039\/D5NH00378D","article-title":"The application and challenges of antimicrobial drug-loaded scaffold materials for the treatment of bone infections","volume":"10","author":"Wu","year":"2025","journal-title":"Nanoscale Horiz."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"121832","DOI":"10.1016\/j.ijpharm.2022.121832","article-title":"Poly(DL-lactic acid) scaffolds as a bone targeting platform for the co-delivery of antimicrobial agents against mixed biofilms","volume":"622","author":"Zegre","year":"2022","journal-title":"Int. J. Pharm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"124311","DOI":"10.1016\/j.carbpol.2025.124311","article-title":"3D-printed chitosan-starch mesh filled with minocycline-alginate hydrogel for dual anti and osteogenic effects","volume":"370","author":"Cardoso","year":"2025","journal-title":"Carbohyd Polym."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"125480","DOI":"10.1016\/j.ijpharm.2025.125480","article-title":"Dual-Loaded Chitosan-Based Nanoparticles: A Novel approach for treating polymicrobial osteomyelitis","volume":"674","author":"Zegre","year":"2025","journal-title":"Int. J. Pharm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1302\/0301-620X.103B2.BJJ-2020-0452.R2","article-title":"Bacteriophage therapy for bone and joint infections","volume":"103","author":"Gibb","year":"2021","journal-title":"Bone Jt. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e70280","DOI":"10.1002\/mco2.70280","article-title":"Phage and Endolysin Therapy Against Antibiotics Resistant Bacteria: From Bench to Bedside","volume":"6","author":"Mohebi","year":"2025","journal-title":"MedComm"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Aitken, M., Abeysekera, G., Billington, C., and Dobson, R.C.J. (2025). Recent Advances in Endolysin Engineering. Antibiotics, 14.","DOI":"10.3390\/antibiotics14121285"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12929-023-00919-1","article-title":"Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria","volume":"30","author":"Liu","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Khan, F.M., Rasheed, F., Yang, Y., Liu, B., and Zhang, R. (2024). Endolysins: A new antimicrobial agent against antimicrobial resistance. Strategies and opportunities in overcoming the challenges of endolysins against Gram-negative bacteria. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1385261"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e02231-19","DOI":"10.1128\/AAC.02231-19","article-title":"Evaluation of the Activity of a Combination of Three Bacteriophages Alone or in Association with Antibiotics on Staphylococcus aureus Embedded in Biofilm or Internalized in Osteoblasts","volume":"64","author":"Kolenda","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Wang, L., Tkhilaishvili, T., and Trampuz, A. (2020). Adjunctive Use of Phage Sb-1 in Antibiotics Enhances Inhibitory Biofilm Growth Activity versus Rifampin-Resistant Staphylococcus aureus Strains. Antibiotics, 9.","DOI":"10.3390\/antibiotics9110749"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Latz, S., Kr\u00fcttgen, A., H\u00e4fner, H., Buhl, E.M., Ritter, K., and Horz, H.-P. (2017). Differential Effect of Newly Isolated Phages Belonging to PB1-Like, phiKZ-Like and LUZ24-Like Viruses against Multi-Drug Resistant Pseudomonas aeruginosa under Varying Growth Conditions. Viruses, 9.","DOI":"10.3390\/v9110315"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/1040841X.2012.723675","article-title":"Bacteriophage virion-associated peptidoglycan hydrolases: Potential new enzybiotics","volume":"39","author":"Martinez","year":"2013","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Gutierrez, D., Ruas-Madiedo, P., Martinez, B., Rodriguez, A., and Garcia, P. (2014). Effective removal of staphylococcal biofilms by the endolysin LysH5. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0107307"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e02666-16","DOI":"10.1128\/AAC.02666-16","article-title":"Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent","volume":"61","author":"Schuch","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1302\/0301-620X.102B7.BJJ-2019-1590.R1","article-title":"2020 John Charnley Award: The antimicrobial potential of bacteriophage-derived lysin in a murine debridement, antibiotics, and implant retention model of prosthetic joint infection","volume":"102","author":"Sosa","year":"2020","journal-title":"Bone Jt. J"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e0185122","DOI":"10.1128\/mbio.01851-22","article-title":"Phage-Plasmids Spread Antibiotic Resistance Genes through Infection and Lysogenic Conversion","volume":"13","author":"Pfeifer","year":"2022","journal-title":"mBio"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/jor.70029","article-title":"Activity of Phage and Vancomycin in a Murine Staphylococcus aureus Periprosthetic Joint Infection Model Managed with Debridement and Implant Retention","volume":"43","author":"Herren","year":"2025","journal-title":"J. Orthop. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2106\/JBJS.K.01135","article-title":"Bacteriophage therapy in implant-related infections: An experimental study","volume":"95","author":"Yilmaz","year":"2013","journal-title":"J. Bone Jt. Surg. Am."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Morris, J.L., Letson, H.L., Elliott, L., Grant, A.L., Wilkinson, M., Hazratwala, K., and McEwen, P. (2019). Evaluation of bacteriophage as an adjunct therapy for treatment of peri-prosthetic joint infection caused by Staphylococcus aureus. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0226574"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/0971-5916.178615","article-title":"Phage therapy of staphylococcal chronic osteomyelitis in experimental animal model","volume":"143","author":"Kishor","year":"2016","journal-title":"Indian. J. Med. Res."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Peez, C., Chen, B., Henssler, L., Chitto, M., Onsea, J., Verhofstad, M.H.J., Arens, D., Constant, C., Zeiter, S., and Obremskey, W. (2025). Evaluating the safety, pharmacokinetics and efficacy of phage therapy in treating fracture-related infections with multidrug-resistant Staphylococcus aureus: Intravenous versus local application in sheep. Front. Cell Infect. Microbiol., 15.","DOI":"10.3389\/fcimb.2025.1547250"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40121-024-01069-z","article-title":"Phage-Derived Endolysins Against Resistant Staphylococcus spp.: A Review of Features, Antibacterial Activities, and Recent Applications","volume":"14","author":"Golban","year":"2025","journal-title":"Infect. Dis. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e01462-20","DOI":"10.1128\/mBio.01462-20","article-title":"Phage-Antibiotic Synergy Is Driven by a Unique Combination of Antibacterial Mechanism of Action and Stoichiometry","volume":"11","author":"Green","year":"2020","journal-title":"mBio"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e0321923","DOI":"10.1128\/spectrum.03219-23","article-title":"Exploiting phage-antibiotic synergies to disrupt Pseudomonas aeruginosa PAO1 biofilms in the context of orthopedic infections","volume":"12","author":"Kamarudin","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jbm.a.36790","article-title":"Bacteriophage delivering hydrogels reduce biofilm formation in vitro and infection in vivo","volume":"108","author":"Wroe","year":"2020","journal-title":"J. Biomed. Mater. Res. A"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Zimecki, M., Artym, J., Kocieba, M., Weber-Dabrowska, B., Borysowski, J., and Gorski, A. (2009). Effects of prophylactic administration of bacteriophages to immunosuppressed mice infected with Staphylococcus aureus. BMC Microbiol., 9.","DOI":"10.1186\/1471-2180-9-169"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e01235-19","DOI":"10.1128\/AAC.01235-19","article-title":"Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats","volume":"63","author":"Karau","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e00117-21","DOI":"10.1128\/AAC.00117-21","article-title":"Activity of Lysin CF-296 Alone and in Addition to Daptomycin in a Rat Model of Experimental Methicillin-Resistant Staphylococcus aureus Osteomyelitis","volume":"65","author":"Karau","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1128\/AAC.02526-12","article-title":"Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus","volume":"57","author":"Gilmer","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e37489","DOI":"10.1016\/j.heliyon.2024.e37489","article-title":"Bacteriophage as a potential biotherapeutics to combat present-day crisis of multi-drug resistant pathogens","volume":"10","author":"Pattnaik","year":"2024","journal-title":"Heliyon"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2562634","DOI":"10.1080\/21505594.2025.2562634","article-title":"Next-generation antimicrobials: A review of phage lysins as precision weapons against drug-resistant pathogens","volume":"16","author":"Cui","year":"2025","journal-title":"Virulence"},{"key":"ref_74","first-page":"167","article-title":"A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans","volume":"69","author":"Harb","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"ofy269","DOI":"10.1093\/ofid\/ofy269","article-title":"Salvage Debridement, Antibiotics and Implant Retention (\u201cDAIR\u201d) with Local Injection of a Selected Cocktail of Bacteriophages: Is It an Option for an Elderly Patient with Relapsing Staphylococcus aureus Prosthetic-Joint Infection?","volume":"5","author":"Ferry","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e00924-19","DOI":"10.1128\/AAC.00924-19","article-title":"Bacteriophages as Adjuvant to Antibiotics for the Treatment of Periprosthetic Joint Infection Caused by Multidrug-Resistant Pseudomonas aeruginosa","volume":"64","author":"Tkhilaishvili","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Clarke, A.L., De Soir, S., and Jones, J.D. (2020). The Safety and Efficacy of Phage Therapy for Bone and Joint Infections: A Systematic Review. Antibiotics, 9.","DOI":"10.3390\/antibiotics9110795"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Doub, J.B., Ng, V.Y., Johnson, A.J., Slomka, M., Fackler, J., Horne, B.A., Brownstein, M.J., Henry, M., Malagon, F., and Biswas, B. (2020). Salvage Bacteriophage Therapy for a Chronic MRSA Prosthetic Joint Infection. Antibiotics, 9.","DOI":"10.3390\/antibiotics9050241"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Ferry, T., Batailler, C., Souche, A., Cassino, C., Chidiac, C., Perpoint, T., le Corvaisier, C., Josse, J., Gaillard, R., and Roger, J. (2021). Arthroscopic \u201cDebridement and Implant Retention\u201d with Local Administration of Exebacase (Lysin CF-301) Followed by Suppressive Tedizolid as Salvage Therapy in Elderly Patients for Relapsing Multidrug-Resistant S. epidermidis Prosthetic Knee Infection. Front. Med., 8.","DOI":"10.3389\/fmed.2021.550853"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1302\/2058-5241.6.210073","article-title":"A systematic review of phage therapy applied to bone and joint infections: An analysis of success rates, treatment modalities and safety","volume":"6","author":"Geneviere","year":"2021","journal-title":"EFORT Open Rev."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Glowacka-Rutkowska, A., Gozdek, A., Empel, J., Gawor, J., Zuchniewicz, K., Kozinska, A., Debski, J., Gromadka, R., and Lobocka, M. (2018). The Ability of Lytic Staphylococcal Podovirus vB_SauP_phiAGO1.3 to Coexist in Equilibrium with Its Host Facilitates the Selection of Host Mutants of Attenuated Virulence but Does Not Preclude the Phage Antistaphylococcal Activity in a Nematode Infection Model. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.03227"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Glowacka-Rutkowska, A., Ulatowska, M., Empel, J., Kowalczyk, M., Boreczek, J., and Lobocka, M. (2020). A Kayvirus Distant Homolog of Staphylococcal Virulence Determinants and VISA Biomarker Is a Phage Lytic Enzyme. Viruses, 12.","DOI":"10.3390\/v12030292"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/B978-0-12-394438-2.00005-0","article-title":"Genomics of staphylococcal Twort-like phages--potential therapeutics of the post-antibiotic era","volume":"83","author":"Lobocka","year":"2012","journal-title":"Adv. Virus Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1473-3099(18)30482-1","article-title":"Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): A randomised, controlled, double-blind phase 1\/2 trial","volume":"19","author":"Jault","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_85","first-page":"001390","article-title":"Methicillin-sensitive Staphylococcus aureus lineages contribute towards poor patient outcomes in orthopaedic device-related infections","volume":"11","author":"Post","year":"2025","journal-title":"Microb. Genom."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Stacey, H.J., De Soir, S., and Jones, J.D. (2022). The Safety and Efficacy of Phage Therapy: A Systematic Review of Clinical and Safety Trials. Antibiotics, 11.","DOI":"10.3390\/antibiotics11101340"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e177383","DOI":"10.1172\/JCI177383","article-title":"Building reproducible bridges to cross the \u201cvalley of death\u201d","volume":"134","author":"Errington","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ebiom.2015.12.023","article-title":"Oral Phage Therapy of Acute Bacterial Diarrhea with Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh","volume":"4","author":"Sarker","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_89","unstructured":"MedPath (2025, December 26). Phaxiam Therapeutics\u2019 PhagoDAIR Study Shows Promising Infection Control with Phage Therapy. Available online: https:\/\/trial.medpath.com\/news\/317147f6867fbdda\/phaxiam-therapeutics-presents-clinical-data-of-the-phagodair-pilot-study-with-results."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e18742858281566","DOI":"10.2174\/0118742858281566231221045303","article-title":"Phage Therapy: Clinical Applications, Efficacy, and Implementation Hurdles","volume":"18","author":"Fowoyo","year":"2024","journal-title":"Open Microbiol. J."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Ortiz-Cartagena, C., Blasco, L., Bleriot, I., Esteban, J., del Toro, M.D., del Pozo, J.L., and Tom\u00e1s, M. (2025). Phage Therapy for Bone and Joint Infections: Towards Clinical Translation. Antibiotics, 14.","DOI":"10.3390\/antibiotics14121187"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Wacnik, M., Hauza, E., Skaradzi\u0144ska, A., and \u015aliwka, P. (2026). Bacteriophage Therapy: Overcoming Antimicrobial Resistance Through Advanced Delivery Methods. Molecules, 31.","DOI":"10.3390\/molecules31020324"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Dicks, L.M.T., and Vermeulen, W. (2024). Bacteriophage\u2013Host Interactions and the Therapeutic Potential of Bacteriophages. Viruses, 16.","DOI":"10.3390\/v16030478"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"35","DOI":"10.20517\/mrr.2025.31","article-title":"Phage therapy as a revitalized weapon for treating clinical diseases","volume":"4","author":"Wang","year":"2025","journal-title":"Microbiome Res. Rep."},{"key":"ref_95","first-page":"168","article-title":"The disparate effects of bacteriophages on antibiotic-resistant bacteria","volume":"7","year":"2018","journal-title":"Emerg. Microbes Infect."}],"container-title":["Applied Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3417\/16\/4\/2002\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T08:03:42Z","timestamp":1771401822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3417\/16\/4\/2002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":95,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["app16042002"],"URL":"https:\/\/doi.org\/10.3390\/app16042002","relation":{},"ISSN":["2076-3417"],"issn-type":[{"value":"2076-3417","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]}}}